Tangen Biosciences, Inc., has developed a rapid, highly sensitive, exceptionally capable, and economical molecular diagnostic platform. Tangen created a group of proprietary technologies that have been integrated to provide the speed, ease of use, and sensitivity required to create a breakthrough molecular diagnostic platform. The extreme sensitivity of the Tangen platform allows it to be applied to indications that were previously thought to be out of reach of molecular diagnostic systems. The platform will enable fast, reliable assay results that may aid in patient management by improving the quality of care and patient outcomes, while reducing costs.
Tangen was founded in 2013 and began the development of a hand-sized, portable, high speed, sample-to-answer molecular diagnostic platform. Tangen has built a team that has extensive experience in the design and manufacture of molecular-based research instruments, as well as experience in business development, operations, marketing, clinical trials, and in regulatory requirements, and is uniquely suited to develop and launch this product. The company is located in Branford, CT.
There is currently an unmet need in the market for truly flexible nucleic acid-based diagnostic devices, which Tangen’s platform, the Tangen Molecular Diagnostic System (TangenDx™) is designed to fill. What sets TangenDx™ apart from competitors is the capability to detect a broad array of targets simultaneously on a single sample, while maintaining low cost, easy workflow, and extreme sensitivity. We believe that this is the future of diagnostics, and a technology such as the TangenDx™ will eventually bring high quality molecular testing to the traditional laboratory setting, and also to settings outside the laboratory, such as clinics, doctor’s offices, pharmacies, and even into the hands of rural health care providers in less developed regions of the world.